PRMTs appear to play a nonnegligible role in cancer treatment.[31] Among them, PRMT3 has been reported to be involved in the regulation of glycolysis through the modification of GAPDH and LDHA.[11, 13] Moreover, PRMT3 can recognize c‐MYC, HIF‐1α, and hnRNPA1 as substrates to affect gene expression in cancer cells.[12, 14, 32] However, even so, PRMT3 is still an understudied field in EC. The gene discussed is GAPDH; the disease is cancer.